Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives $38.50 Average Price Target from Brokerages

Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) have been given an average recommendation of “Moderate Buy” by the thirteen analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eleven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $38.50.

A number of brokerages have recently weighed in on CNTA. B. Riley boosted their price target on Centessa Pharmaceuticals from $33.00 to $42.00 and gave the stock a “buy” rating in a research note on Monday, December 1st. Oppenheimer boosted their target price on shares of Centessa Pharmaceuticals from $40.00 to $62.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 10th. Guggenheim upped their price target on shares of Centessa Pharmaceuticals from $28.00 to $43.00 and gave the company a “buy” rating in a research note on Tuesday, November 18th. Truist Financial lifted their price objective on shares of Centessa Pharmaceuticals from $33.00 to $38.00 and gave the stock a “buy” rating in a research note on Thursday, January 29th. Finally, Wall Street Zen raised shares of Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, October 27th.

Insider Buying and Selling at Centessa Pharmaceuticals

In related news, CTO Tia L. Bush sold 40,000 shares of the stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $26.00, for a total value of $1,040,000.00. Following the transaction, the chief technology officer owned 121,503 shares in the company, valued at approximately $3,159,078. This represents a 24.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mario Alberto Accardi sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $30.00, for a total transaction of $300,000.00. Following the transaction, the insider directly owned 178,801 shares of the company’s stock, valued at $5,364,030. This represents a 5.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 89,961 shares of company stock worth $2,344,878. 7.09% of the stock is currently owned by insiders.

Institutional Trading of Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Avoro Capital Advisors LLC lifted its position in Centessa Pharmaceuticals by 116.2% during the third quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock valued at $262,096,000 after purchasing an additional 5,808,080 shares during the period. Federated Hermes Inc. purchased a new position in shares of Centessa Pharmaceuticals during the 3rd quarter valued at about $42,429,000. Adage Capital Partners GP L.L.C. raised its stake in shares of Centessa Pharmaceuticals by 20.8% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,403,000 shares of the company’s stock valued at $110,415,000 after buying an additional 1,449,000 shares during the last quarter. Balyasny Asset Management L.P. acquired a new position in shares of Centessa Pharmaceuticals in the 2nd quarter valued at about $16,052,000. Finally, Commodore Capital LP boosted its stake in shares of Centessa Pharmaceuticals by 39.3% in the second quarter. Commodore Capital LP now owns 3,298,289 shares of the company’s stock worth $43,340,000 after buying an additional 930,711 shares during the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA stock opened at $23.54 on Friday. Centessa Pharmaceuticals has a 12-month low of $9.60 and a 12-month high of $30.58. The business’s fifty day simple moving average is $25.22 and its 200-day simple moving average is $22.62. The company has a current ratio of 10.56, a quick ratio of 10.57 and a debt-to-equity ratio of 0.36. The company has a market cap of $3.16 billion, a PE ratio of -12.86 and a beta of 1.56.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.02). Analysts expect that Centessa Pharmaceuticals will post -1.6 earnings per share for the current fiscal year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.